Bioretec signed a distribution agreement to accelerate commercialization of the RemeOs trauma screw system in the U.S., according to a Nov. 22 news release.
The sales and distribution agreement was with Tri-State Biologics, which provides instruments and implants to hospitals in Greater New York City, Philadelphia, New Jersey, Connecticut, and Massachusetts.
Bioretec plans to sign more local sales agreements in the U.S. as part of the next phase of RemeOs traume screw commercialization.
The RemeOs product line is based on a magnesium alloy and hybrid composite, and implants are resorbed and replaced by bone.